Vaxil Publishes The Results Of Its Phase 1/2 Study Using Immucin In Myeloma Patients In The "British Journal Of Hematology"
The article summarizes the results of the successful Phase I/II study using ImMucin to treat patients with Multiple Myeloma (a haematological cancer)
Ness Ziona, 15th December 2014. Vaxil Bio (TASE: VAXL), which is developing immunotherapeutic products to treat cancer and infectious diseases, reports today that it has published the results of its recent clinical trial (VAXIL-001) in Multiple Myeloma patients. The article, available on-line as of December 14th in the Scientific Journal British Journal of Hematology, (link attached), discusses the clinical trial in 15 Multiple Myeloma patients who were experiencing gradual return of their disease following a period of remission and who were treated with ImMucin. http://onlinelibrary.wiley.com/doi/10.1111/bjh.13245/abstract
Patients were treated with 6 or 12 injections of ImMucin over a 6 month period. The drug was exceptionally well tolerated with minimal side effects. In addition, there was a broad and robust immunological response from 100% of the patients, of both CD4 and CD8 T-cells, and an antibody response from 66% of the patients. This combined T-cell an antibody response is unique and highly needed for tumor eradication. Moreover, a significant decrease in soluble MUC1 levels in patient’s blood was observed in 90% of patients having abnormal levels pre-treatment and is believed to indicate tumor cells destruction. Very encouragingly, at the end of the study 11 out of the 15 patients achieved stable disease or improvement, persisting for 17.5 to 41.3 months (still ongoing). Interestingly, patients with low to intermediate PDL1 seemed to react best to the treatment, suggesting that this patient population is less likely to benefit from a treatment with PD1/PD-L1 immune check point inhibition.
Dr. Lior Carmon Vaxil's founder and CEO: "This article is an important validation for our technological approach which the scientific and medical community has been awaiting. The results we saw were highly encouraging and Vaxil is continuing with its clinical development of ImMucin towards a Phase II study in MM. We are also exploring ImMucin's application in other relevant cancers and to that end have started testing it in patients with metastatic breast cancer. "
Help employers find you! Check out all the jobs and post your resume.
Ness Ziona, 15th December 2014. Vaxil Bio (TASE: VAXL), which is developing immunotherapeutic products to treat cancer and infectious diseases, reports today that it has published the results of its recent clinical trial (VAXIL-001) in Multiple Myeloma patients. The article, available on-line as of December 14th in the Scientific Journal British Journal of Hematology, (link attached), discusses the clinical trial in 15 Multiple Myeloma patients who were experiencing gradual return of their disease following a period of remission and who were treated with ImMucin. http://onlinelibrary.wiley.com/doi/10.1111/bjh.13245/abstract
Patients were treated with 6 or 12 injections of ImMucin over a 6 month period. The drug was exceptionally well tolerated with minimal side effects. In addition, there was a broad and robust immunological response from 100% of the patients, of both CD4 and CD8 T-cells, and an antibody response from 66% of the patients. This combined T-cell an antibody response is unique and highly needed for tumor eradication. Moreover, a significant decrease in soluble MUC1 levels in patient’s blood was observed in 90% of patients having abnormal levels pre-treatment and is believed to indicate tumor cells destruction. Very encouragingly, at the end of the study 11 out of the 15 patients achieved stable disease or improvement, persisting for 17.5 to 41.3 months (still ongoing). Interestingly, patients with low to intermediate PDL1 seemed to react best to the treatment, suggesting that this patient population is less likely to benefit from a treatment with PD1/PD-L1 immune check point inhibition.
Dr. Lior Carmon Vaxil's founder and CEO: "This article is an important validation for our technological approach which the scientific and medical community has been awaiting. The results we saw were highly encouraging and Vaxil is continuing with its clinical development of ImMucin towards a Phase II study in MM. We are also exploring ImMucin's application in other relevant cancers and to that end have started testing it in patients with metastatic breast cancer. "
Help employers find you! Check out all the jobs and post your resume.